As previously reported, Guggenheim initiated coverage of GeneDx (WGS) with a Buy rating and $88 price target The company has established “an increasingly sticky leadership position” in the rare disease genetic testing market as strong execution and an increasingly differentiated and proprietary database for rare diseases positions the company to drive continued double-digit revenue growth while becoming increasingly profitable, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx initiated with a Buy at Guggenheim
- GeneDx Holdings: Positioned for Growth in Whole Genome Sequencing with Strong NICU Market Potential
- GeneDx management to meet with BTIG
- GeneDx Holdings: Strong Buy Rating Backed by Projected Growth and Competitive Edge
- GeneDx upgraded to Buy from Hold at Jefferies
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue